Clinical Trial Update: A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) [Phase 2]

View source ↗

Summary

This update covers a Phase 2 study (MTAPESTRY 201) of Anvumetostat in MTAP-deleted advanced non-small cell lung cancer, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anvumetostat (Anvumetostat)

Snippet

Sponsor: Amgen | Conditions: MTAP-deleted NSCLC | Phase 2 | Status: RECRUITING